sb-485232
Recombinant proteinexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2003 (NCT00085878)
Timeline
Indications
Mechanism of action
- Interleukin-18Supplementation
IL18 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sb-485232
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01768338 | Phase 1 | Feb 1, 2013 | Indiana University, Novartis |
| NCT00107718 | Phase 2 | Nov 1, 2004 | GlaxoSmithKline |
| NCT00085904 | Phase 1 | Apr 1, 2004 | GlaxoSmithKline |
| NCT00085878 | Phase 1 | Jan 1, 2003 | GlaxoSmithKline |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 2 | 2003 |
| Indiana University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Novartis | For profit | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1